BUZZ-Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing
I'm PortAI, I can summarize articles.
Agios Pharmaceuticals' shares fell 7.5% premarket after the FDA missed the decision deadline on expanding the use of its drug mitapivat for thalassemia. The drug, already approved for another blood disorder, aims to enhance enzyme activity in red blood cells. The FDA has not provided a new timeline, and Agios is collaborating with the agency to conclude the review. AGIO stock is down 15.6% year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments